Evidence map›Paper›PMID 35693342›Full record

ArticleFrontiers in aging neuroscience2022

A Novel Key Features Screening Method Based on Extreme Learning Machine for Alzheimer's Disease Study.

Jia Lu, Weiming Zeng, Lu Zhang, Yuhu Shi

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jia LuLaboratory of Digital Image and Intelligent Computation, Shanghai Maritime University, Shanghai, China.
Weiming ZengLaboratory of Digital Image and Intelligent Computation, Shanghai Maritime University, Shanghai, China.
Lu ZhangBasic Experiment and Training Center, Shanghai Maritime University, Shanghai, China.
Yuhu ShiCollege of Information Engineering Shanghai Maritime University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Extreme Learning Machine (ELM) is a simple and efficient Single Hidden Layer Feedforward Neural Network(SLFN) algorithm. In recent years, it has been gradually used in the study of Alzheimer's disease (AD). When using ELM to diagnose AD based on high-dimensional features, there are often some features that have no positive impact on the diagnosis, while others have a significant impact on the diagnosis. In this paper, a novel Key Features Screening Method based on Extreme Learning Machine (KFS-ELM) is proposed. It can screen for key features that are relevant to the classification (diagnosis). It can also assign weights to key features based on their importance. We designed an experiment to screen for key features of AD. A total of 920 key functional connections screened from 4005 functional connections. Their weights were also obtained. The results of the experiment showed that: (1) Using all (4,005) features to diagnose AD, the accuracy is 95.33%. Using 920 key features to diagnose AD, the accuracy is 99.20%. The 3,085 (4,005 - 920) features that were screened out had a negative effect on the diagnosis of AD. This indicates the KFS-ELM is effective in screening key features. (2) The higher the weight of the key features and the smaller their number, the greater their impact on AD diagnosis. This indicates that the KFS-ELM is rational in assigning weights to the key features for their importance. Therefore, KFS-ELM can be used as a tool for studying features and also for improving classification accuracy.

Indexed as

ADbrain functional connectivityextreme learning machinefMRIKFS-ELM

Identifiers

PMID35693342
PMCPMC9177228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.